202 related articles for article (PubMed ID: 27156193)
1. Design and synthesis of peptide conjugates of phosphoramide mustard as prodrugs activated by prostate-specific antigen.
Wu X; Hu L
Bioorg Med Chem; 2016 Jun; 24(12):2697-706. PubMed ID: 27156193
[TBL] [Abstract][Full Text] [Related]
2. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA).
Jiang Y; Hu L
Bioorg Med Chem; 2013 Dec; 21(23):7507-14. PubMed ID: 24139844
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy.
Gerard Y; Voissière A; Peyrode C; Galmier MJ; Maubert E; Ghedira D; Tarrit S; Gaumet V; Canitrot D; Miot-Noirault E; Chezal JM; Weber V
Bioorg Chem; 2020 May; 98():103747. PubMed ID: 32208207
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA).
Jiang Y; Dipaola RS; Hu L
Bioorg Med Chem Lett; 2009 May; 19(9):2587-90. PubMed ID: 19345094
[TBL] [Abstract][Full Text] [Related]
5. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramide mustards for E. coli nitroreductase activation.
Jiang Y; Han J; Yu C; Vass SO; Searle PF; Browne P; Knox RJ; Hu L
J Med Chem; 2006 Jul; 49(14):4333-43. PubMed ID: 16821793
[TBL] [Abstract][Full Text] [Related]
7. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
8. Improving the Specificity of the Prostate-Specific Antigen Substrate Glutaryl-Hyp-Ala-Ser-Chg-Gln as a Promoiety.
Aloysius H; Hu L
Chem Biol Drug Des; 2015 Oct; 86(4):837-48. PubMed ID: 25777622
[TBL] [Abstract][Full Text] [Related]
9. Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: synthesis, stability, and stereochemical requirements for enzymatic cleavage.
Jiang Y; Hu L
Bioorg Med Chem Lett; 2007 Jan; 17(2):517-21. PubMed ID: 17064897
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase.
Hernick M; Flader C; Borch RF
J Med Chem; 2002 Aug; 45(16):3540-8. PubMed ID: 12139465
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells.
Roth T; Tang W; Eisenbrand G
Anticancer Drug Des; 1995 Dec; 10(8):655-66. PubMed ID: 8595124
[TBL] [Abstract][Full Text] [Related]
12. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs.
Hu L; Wu X; Han J; Chen L; Vass SO; Browne P; Hall BS; Bot C; Gobalakrishnapillai V; Searle PF; Knox RJ; Wilkinson SR
Bioorg Med Chem Lett; 2011 Jul; 21(13):3986-91. PubMed ID: 21620697
[TBL] [Abstract][Full Text] [Related]
14. Acyloxymethyl esters of isophosphoramide mustard as new anticancer prodrugs.
Cytarska J; Misiura K; Filip-Psurska B; Wietrzyk J
Acta Pol Pharm; 2013; 70(3):481-7. PubMed ID: 23757939
[TBL] [Abstract][Full Text] [Related]
15. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
16. Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.
Bakthavatsalam S; Wiangnak P; George DJ; Zhang T; Franz KJ
Bioorg Med Chem Lett; 2020 Jun; 30(11):127148. PubMed ID: 32253061
[TBL] [Abstract][Full Text] [Related]
17. Chemically stable, lipophilic prodrugs of phosphoramide mustard as potential anticancer agents.
Kwon CH; Moon KY; Baturay N; Shirota FN
J Med Chem; 1991 Feb; 34(2):588-92. PubMed ID: 1995881
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs.
Lin S; Li Y; Zheng Y; Luo L; Sun Q; Ge Z; Cheng T; Li R
Eur J Med Chem; 2017 Feb; 127():442-458. PubMed ID: 28092860
[TBL] [Abstract][Full Text] [Related]
20. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]